JPWO2022075439A1 - - Google Patents
Info
- Publication number
- JPWO2022075439A1 JPWO2022075439A1 JP2022555581A JP2022555581A JPWO2022075439A1 JP WO2022075439 A1 JPWO2022075439 A1 JP WO2022075439A1 JP 2022555581 A JP2022555581 A JP 2022555581A JP 2022555581 A JP2022555581 A JP 2022555581A JP WO2022075439 A1 JPWO2022075439 A1 JP WO2022075439A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020170478 | 2020-10-08 | ||
| PCT/JP2021/037296 WO2022075439A1 (ja) | 2020-10-08 | 2021-10-08 | 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2022075439A1 true JPWO2022075439A1 (https=) | 2022-04-14 |
Family
ID=81126520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555581A Pending JPWO2022075439A1 (https=) | 2020-10-08 | 2021-10-08 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240288453A1 (https=) |
| EP (1) | EP4227686A4 (https=) |
| JP (1) | JPWO2022075439A1 (https=) |
| CN (1) | CN116472282A (https=) |
| WO (1) | WO2022075439A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020105621A1 (ja) * | 2018-11-20 | 2020-05-28 | 株式会社ペルセウスプロテオミクス | 細胞内への鉄の取り込み阻害剤 |
| EP4026560A4 (en) * | 2019-09-04 | 2023-10-25 | Perseus Proteomics Inc. | THERAPEUTIC AGENT AGAINST POLYCYTHEMIA |
| US20250263497A1 (en) * | 2022-04-19 | 2025-08-21 | Tokai University Educational System | Therapeutic agent for nk-cell tumor |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006517032A (ja) * | 2003-01-28 | 2006-07-13 | ジョージタウン・ユニバーシティ | ある種の癌治療の有効性を評価するための方法 |
| JP2008508904A (ja) * | 2004-06-07 | 2008-03-27 | レイヴェン バイオテクノロジーズ， インコーポレイテッド | トランスフェリンレセプター抗体 |
| JP2008303168A (ja) * | 2007-06-07 | 2008-12-18 | Japan Health Science Foundation | 破骨細胞制御剤とそのスクリーニング方法 |
| US20130171061A1 (en) * | 2011-12-29 | 2013-07-04 | Ming-Hua Yang | Anti-human transferrin receptor antibody and uses thereof |
| JP2014093958A (ja) * | 2012-11-08 | 2014-05-22 | Univ Of Miyazaki | トランスフェリン受容体を特異的に認識できる抗体 |
| WO2015108172A1 (ja) * | 2014-01-17 | 2015-07-23 | 岐阜市 | 鉄（ｉｉ）イオン検出剤及びそれを用いた検出方法 |
| US20190101549A1 (en) * | 2016-03-09 | 2019-04-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Total cellular iron as a marker of cancer stem cells and uses thereof |
| WO2020105621A1 (ja) * | 2018-11-20 | 2020-05-28 | 株式会社ペルセウスプロテオミクス | 細胞内への鉄の取り込み阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| ATE208374T1 (de) | 1992-02-18 | 2001-11-15 | Otsuka Kagaku Kk | Beta-laktam und cepham verbindungen und ihre herstellung |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| PT1740616E (pt) | 2004-04-30 | 2012-03-23 | Inst Nat Sante Rech Med | Anticorpo anti-rtf |
| CA2893794C (en) * | 2012-11-08 | 2021-11-09 | University Of Miyazaki | Antibody capable of specifically recognizing transferrin receptor |
| WO2020104479A1 (en) * | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
-
2021
- 2021-10-08 US US18/030,534 patent/US20240288453A1/en active Pending
- 2021-10-08 EP EP21877738.1A patent/EP4227686A4/en active Pending
- 2021-10-08 CN CN202180069033.XA patent/CN116472282A/zh active Pending
- 2021-10-08 WO PCT/JP2021/037296 patent/WO2022075439A1/ja not_active Ceased
- 2021-10-08 JP JP2022555581A patent/JPWO2022075439A1/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006517032A (ja) * | 2003-01-28 | 2006-07-13 | ジョージタウン・ユニバーシティ | ある種の癌治療の有効性を評価するための方法 |
| JP2008508904A (ja) * | 2004-06-07 | 2008-03-27 | レイヴェン バイオテクノロジーズ， インコーポレイテッド | トランスフェリンレセプター抗体 |
| JP2008303168A (ja) * | 2007-06-07 | 2008-12-18 | Japan Health Science Foundation | 破骨細胞制御剤とそのスクリーニング方法 |
| US20130171061A1 (en) * | 2011-12-29 | 2013-07-04 | Ming-Hua Yang | Anti-human transferrin receptor antibody and uses thereof |
| JP2014093958A (ja) * | 2012-11-08 | 2014-05-22 | Univ Of Miyazaki | トランスフェリン受容体を特異的に認識できる抗体 |
| WO2015108172A1 (ja) * | 2014-01-17 | 2015-07-23 | 岐阜市 | 鉄（ｉｉ）イオン検出剤及びそれを用いた検出方法 |
| US20190101549A1 (en) * | 2016-03-09 | 2019-04-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Total cellular iron as a marker of cancer stem cells and uses thereof |
| WO2020105621A1 (ja) * | 2018-11-20 | 2020-05-28 | 株式会社ペルセウスプロテオミクス | 細胞内への鉄の取り込み阻害剤 |
Non-Patent Citations (4)
| Title |
|---|
| CREPIN RONAN ET AL.: "Development of Human Single-Chain Antibodies to the Transferrin Receptor that Effectively Antagonize", CANCER RESEARCH, vol. 70, no. 13, JPN7021005066, 8 June 2010 (2010-06-08), pages 5497 - 5506, ISSN: 0005692670 * |
| NEIVEYANS MADELINE ET AL.: "A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleuke", MABS, vol. 11, no. 3, JPN7021005067, 18 February 2019 (2019-02-18), pages 593 - 605, ISSN: 0005692667 * |
| RUDOLPH NATALIE S. ET AL.: "Regulation of K562 Cell Transferrin Receptors by Exogenous Iron", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 122, no. 3, JPN6021046601, March 1985 (1985-03-01), pages 441 - 450, ISSN: 0005692668 * |
| SHIMOSAKI SHUNSUKE ET AL.: "Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 485, JPN6021046600, 8 February 2017 (2017-02-08), pages 144 - 151, ISSN: 0005692669 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022075439A1 (ja) | 2022-04-14 |
| EP4227686A1 (en) | 2023-08-16 |
| US20240288453A1 (en) | 2024-08-29 |
| EP4227686A4 (en) | 2024-11-06 |
| CN116472282A (zh) | 2023-07-21 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230407 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260327 |